Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $114,647,120 | $106,160,390 | $153,253,500 | $138,479,350 |
| - Cash | $10,346,000 | $11,464,000 | $9,123,000 | $13,979,000 |
| + Debt | $51,200,000 | $41,464,000 | $40,717,000 | $45,596,000 |
| Enterprise Value | $155,501,120 | $136,160,390 | $184,847,500 | $170,096,350 |
| Revenue | $48,300,000 | $45,006,000 | $46,159,000 | $46,385,000 |
| % Growth | 7.3% | -2.5% | -0.5% | – |
| Gross Profit | $27,432,000 | $25,357,000 | $26,490,000 | $26,761,000 |
| % Margin | 56.8% | 56.3% | 57.4% | 57.7% |
| EBITDA | $3,168,000 | $19,366,000 | $19,221,000 | $20,118,000 |
| % Margin | 6.6% | 43% | 41.6% | 43.4% |
| Net Income | -$8,948,000 | $8,025,000 | $6,327,000 | $6,994,000 |
| % Margin | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS Diluted | -4.41 | 3.86 | 2.95 | 3.12 |
| % Growth | -214.2% | 30.8% | -5.4% | – |
| Operating Cash Flow | $15,190,000 | $13,860,000 | $13,066,000 | $16,207,000 |
| Capital Expenditures | -$1,248,000 | -$1,209,000 | -$1,118,000 | -$973,000 |
| Free Cash Flow | $13,942,000 | $12,651,000 | $11,948,000 | $15,234,000 |